| Not Yet Recruiting | Cardiac Evaluation in Hereditary Hemorrhagic Telangiectasia NCT07101575 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HH NCT06659640 | Alnylam Pharmaceuticals | Phase 1 / Phase 2 |
| Enrolling By Invitation | Quality of Life in Patients With Hemorrhagic Telangiectasia NCT06261333 | University Hospital, Essen | — |
| Recruiting | Comprehensive HHT Outcomes Registry of the United States (CHORUS) NCT06259292 | Cure HHT | — |
| Completed | Stress-Echography in Hereditary Haemorrhagic Telangiectasia Patient With Hepatic Involvement NCT05954481 | Hospices Civils de Lyon | N/A |
| Unknown | Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia NCT03850730 | Cure HHT | Phase 1 / Phase 2 |
| Active Not Recruiting | Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz) NCT03850964 | Cure HHT | Phase 2 / Phase 3 |
| Recruiting | Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia NCT05641142 | University Hospital, Clermont-Ferrand | N/A |
| Completed | Sirolimus for Nosebleeds in HHT NCT05269849 | Unity Health Toronto | Phase 2 |
| Completed | Genotype-phenotype Association in Hereditary Hemorrhagic Telangiectasia NCT05550376 | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | — |
| Active Not Recruiting | Ultra-low-dose Chest CT for HHT NCT04874558 | Mayo Clinic | — |
| Active Not Recruiting | Bevacizumab In Hereditary Hemorrhagic Telangiectasia NCT04404881 | Hanny Al-Samkari, MD | Phase 2 |
| Completed | Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT) NCT04646356 | Unity Health Toronto | Phase 2 |
| Recruiting | Influence of Hypoxic Induced Factors in Patients With Hereditary Hemorrhagic Telangiectasia NCT04469517 | University Hospital, Essen | — |
| Completed | Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients NCT04113187 | University Hospital, Bordeaux | Phase 3 |
| Completed | Counseling Intervention in Hereditary Hemorrhagic Telangiectasia in the COVID Era. NCT05752253 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Completed | Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia NCT04139018 | Washington University School of Medicine | Phase 2 |
| Completed | Development of a Quality of Life Measurement Scale in Hereditary Haemorrhagic Telangiectasia (HHT) Disease. NCT03695874 | Hospices Civils de Lyon | — |
| Active Not Recruiting | CHORUS - Comprehensive HHT Outcomes Registry of the United States (Formerly OUR HHT Registry) NCT04150822 | Unity Health Toronto | — |
| Completed | Evaluation of Obstetrical and Neonatal Complications in Hereditary Haemorrhagic Telangiectasia (HHT) NCT03691142 | Hospices Civils de Lyon | — |
| Completed | Prospective Descriptive Study of the Angiogenic T Cell Population in Subjects With Hereditary Hemorrhagic Tela NCT03572556 | Centre Hospitalier Universitaire Dijon | — |
| Unknown | Nationwide Awareness Campaign and Call for Dental Screening for HHT in Germany NCT03549949 | University Hospital, Essen | — |
| Unknown | Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHT NCT02963129 | Hospital Italiano de Buenos Aires | Phase 3 |
| Completed | MRA With Feraheme in HHT NCT02977637 | University of California, Los Angeles | Phase 1 |
| Unknown | Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber NCT02874326 | Radboud University Medical Center | Phase 2 |
| Unknown | Cardiopulmonary Exercise Testing to Evaluate Pulmonary AVMs With and Without Airflow Obstruction NCT02458703 | Imperial College London | N/A |
| Completed | Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I St NCT02287558 | The Cleveland Clinic | Phase 1 |
| Completed | Intranasal Bevacizumab for HHT-Related Epistaxis NCT02389959 | Stanford University | Phase 4 |
| Terminated | Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (H NCT02106520 | Hospices Civils de Lyon | Phase 2 / Phase 3 |
| Completed | At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurolo NCT01931644 | Sanguine Biosciences | — |
| Completed | Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept NCT01752049 | Unity Health Toronto | Phase 1 / Phase 2 |
| Completed | Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia NCT01485224 | Fondazione IRCCS Policlinico San Matteo di Pavia | Phase 2 |
| Completed | Cardiopulmonary Exercise Testing to Evaluate Pulmonary AVMs NCT02436213 | Imperial College London | N/A |
| Completed | Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia NCT01408732 | University of Minnesota | Phase 1 / Phase 2 |
| Active Not Recruiting | Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia NCT01158807 | Unity Health Toronto | — |
| Completed | Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding NCT00389935 | Northport Veterans Affairs Medical Center | Phase 2 |
| Completed | Anti-Estrogen Therapy for Hereditary Hemorrhagic Telangiectasia A Double-Blind Placebo-Controlled Clinical Tri NCT00375622 | Rabin Medical Center | Phase 2 |
| Completed | Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) NCT01031992 | University Hospital, Saarland | Phase 3 |
| Completed | Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic Te NCT00004654 | National Center for Research Resources (NCRR) | Phase 3 |
| Completed | Study of the Natural History and Genotype-Phenotype Correlations of Hereditary Hemorrhagic Telangiectasia Pati NCT00004649 | National Center for Research Resources (NCRR) | — |
| Completed | Phase II Pilot Study of Octreotide, a Somatostatin Octapeptide Analog, for Gastrointestinal Hemorrhage in Horm NCT00004327 | National Center for Research Resources (NCRR) | Phase 2 |